咖啡因在减少成年人便秘的有效性:一个系统性审查
Anya Latthe1, Albert Tan2, Pallavi Latthe2
1Barnsley Hospital NHS Foundation Trust, Barnsley, UK. anya.latthe@nhs.net.
International urogynecology journal
|December 12, 2024
概括
咖啡因 咖啡因是一种咖啡因.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 便秘影响全球14%,其特点是便不频繁或难以通过.
- 咖啡因被假设能刺激结肠的运动性,可能起到药作用.
- 现有的关于咖啡因松作用的研究结果呈现出相互矛盾的结果.
研究的目的:
- 系统地审查和评估咖啡因在缓解成年人便秘方面的有效性.
- 综合现有文献中关于咖啡因对肠道规律性的影响的发现.
主要方法:
- 在多个数据库 (科克兰图书馆,MEDLINE,EMBASE等) 进行了全面的文献搜索. ) 的情况.
- 搜索术语包括"便秘"","和各种形式的"咖啡因".
- 包括8项研究,并使用ROBINS-I和其他工具评估偏差风险.
主要成果:
- 研究检查了咖啡,茶,能量饮料,可可和康布查中的咖啡因.
- 四项研究表明,咖啡因在缓解便秘方面具有潜在的有效性.
- 四项研究表明,便秘症状没有改善或恶化.
- 由于干预措施和结果措施的异质性,元分析是不可行的.
结论:
- 目前关于咖啡因对便秘有效性的证据是矛盾的.
- 需要进一步进行高质量的随机对照试验 (RCT),以确定咖啡因在治疗成人便秘中的作用.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
186
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
186
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
209
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
209
Drugs Affecting GI Tract Motility: Other Laxatives
169
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
169
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Adrenergic Agonists: Mixed-Action Agents
663
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
663


